Akari Therapeutics 13D Filing Shows Charles Steve Theofilos, M.D. Reported A Stake Of 9.99% In The Co As Of May 31, 2024
Portfolio Pulse from Benzinga Newsdesk
Akari Therapeutics' recent SEC 13D filing reveals that Charles Steve Theofilos, M.D. has reported a 9.99% stake in the company as of May 31, 2024.
June 18, 2024 | 8:20 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Charles Steve Theofilos, M.D. has reported a 9.99% stake in Akari Therapeutics as of May 31, 2024, according to an SEC 13D filing. This significant insider ownership could indicate confidence in the company's future prospects.
The 9.99% stake reported by Charles Steve Theofilos, M.D. is a significant insider ownership, which often signals confidence in the company's future prospects. This could positively impact investor sentiment and the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100